Literature DB >> 15473502

The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.

G Rodrigues1, A Bezjak, D Osoba, P Catton, D Tsuji, D Taylor, P Warde.   

Abstract

PURPOSE: To examine the relationship between changes in health-related quality-of-life (HRQOL) on the EORTC Quality of Life Questionnaire (QLQ-C30), and patients' perceptions of HRQOL changes as measured by the Subjective Significance Questionnaire (SSQ). PATIENTS AND METHODS: A total of 101 patients completed the QLQ-C30 on weeks 1, 4 and 7 of radical external-beam radiation therapy (RT) for localized cancer of the prostate. Patients rated their change in physical functioning, emotional functioning, social functioning, and overall/global quality of life (QOL) by completing a seven-category SSQ at weeks 4 and 7. The association between changes in the QLQ-C30 change and the corresponding SSQ ratings were determined by calculation of mean change scores for each SSQ category and by Spearman rank correlation coefficient analysis.
RESULTS: Patients' completion of the QLQ-C30 and SSQ exceeded 95%. Statistically significant changes in fatigue, pain, appetite, diarrhea, and global QOL scores were detected during RT. For patients reporting 'a little' change in global QOL on the SSQ, absolute mean QLQ-C30 change scores ranged between 0 to 15 points with 12/16 mean change scores between 2.5 and 8.5 points. In the entire study sample, correlations between SSQ patient ratings and QLQ-C30 change scores were lower than previously reported, ranging between 0.15 and 0.24 for the four different domains, but were higher when QOL scores producing ceiling effects were omitted.
CONCLUSION: The SSQ and QLQ-C30 may measure related concepts that could assist in the interpretation of changes in scores and in the calibration of the QLQ-C30. However, the nature of this relationship could not be elucidated in this data set because of a lack of variance in HRQOL scores in the study sample. Further investigation should be carried out in study samples with sufficient variance to allow more robust conclusions.

Entities:  

Mesh:

Year:  2004        PMID: 15473502     DOI: 10.1023/B:QURE.0000037494.27127.b5

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  30 in total

1.  Measuring health-related quality of life.

Authors:  D Osoba; I Tannock
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 2.  Assessing the clinical significance of single items relative to summated scores.

Authors:  Jeff A Sloan; Neil Aaronson; Joseph C Cappelleri; Diane L Fairclough; Claudette Varricchio
Journal:  Mayo Clin Proc       Date:  2002-05       Impact factor: 7.616

Review 3.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

4.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; A Willan; L E Griffith
Journal:  J Clin Epidemiol       Date:  1994-01       Impact factor: 6.437

5.  Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer.

Authors:  F Joly; D Brune; J E Couette; F Lesaunier; J F Héron; J Pény; M Henry-Amar
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

6.  Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer.

Authors:  M S Litwin; K A McGuigan
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer.

Authors:  K A McCammon; P Kolm; B Main; P F Schellhammer
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

Review 8.  Methods to explain the clinical significance of health status measures.

Authors:  Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

9.  The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life.

Authors:  M A Sprangers; A Cull; K Bjordal; M Groenvold; N K Aaronson
Journal:  Qual Life Res       Date:  1993-08       Impact factor: 4.147

10.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

View more
  4 in total

1.  Prospective evaluation of fatigue during a course of curative radiotherapy for localised prostate cancer.

Authors:  Cyril Danjoux; Sandra Gardner; Margaret Fitch
Journal:  Support Care Cancer       Date:  2007-03-01       Impact factor: 3.603

2.  Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.

Authors:  Patrick W Sullivan; Parvez M Mulani; Mayer Fishman; Darryl Sleep
Journal:  Qual Life Res       Date:  2007-02-10       Impact factor: 4.147

3.  Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy.

Authors:  Fanxing Hong; Jaclyn L F Bosco; Nigel Bush; Donna L Berry
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

4.  Low incidence of fatigue after hypofractionated stereotactic body radiation therapy for localized prostate cancer.

Authors:  Chiranjeev Dash; Kristina Demas; Sunghae Uhm; Heather N Hanscom; Joy S Kim; Simeng Suy; Kimberly M Davis; Jennifer Sween; Sean Collins; Lucile L Adams-Campbell
Journal:  Front Oncol       Date:  2012-10-17       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.